CVS Health Corp vs Hormel Foods Corp — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Hormel Foods Corp trades at $19.19 (market cap $10.69B). The key difference: CVS Health Corp is far larger — about 10.5× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Hormel Foods Corp for 99 Days on average.
| CVS | HRL | |
|---|---|---|
Market Cap | $112.29B | $10.69B |
Volume | 7,763,676 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $26.50 |
52-Week Low | $70.08 | $19.19 |
Typical Hold Time | 83 Days | 99 Days |
Enterprise Value | $174.64B | $12.67B |
Dividend Yield | 3.03% | 6.02% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% with a bearish technical signal. The company shows strong revenue growth to $402.1B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus is overwhelmingly bullish with 85% buy ratings and a $111.20 price target representing 27% upside. Recent news highlights Aetna's 2027 Medicare plan enhancements and quarterly dividend declarations.
CVS presents a compelling value opportunity with attractive valuation metrics (P/E 23.17, P/S 0.27) and strong analyst support. Key risks include reimbursement pressure, regulatory scrutiny from ongoing investigations, and declining net margins. The stock's current technical weakness contrasts with solid fundamentals and positive earnings momentum.
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though it has beaten EPS estimates in recent quarters. Recent news highlights the $1.06B Brakebush acquisition to expand foodservice presence, while maintaining its 60-year dividend king status with a quarterly payout of $0.2925.
The outlook is cautious with analyst consensus at Buy 20%/Hold 57%/Sell 23% and a $24.25 price target suggesting 25% upside. Key risks include declining profit margins, high payout ratio concerns, and integration challenges from the Brakebush acquisition. The stock offers dividend stability but faces growth headwinds in a competitive food sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →